With its new deal with Eli Lilly and Co., Deltagen Inc. has launched its migration from gene function specialist into downstream product development.

While DGEN has developed a database of gene function information that is creating revenues on a subscription basis, it also is using its abilities to perform in vivo gene function validation as leverage to obtain needed targets and services.